Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health ...

Researchers at the University of Oxford and their collaborators, including the Serum Institute of India, have developed an innovative method to identify falsified vaccines without opening the vaccine ...

RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman ...

Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

High vaccine wastage and low vaccination and booster rates marred the government’s P74.68-million COVID-19 National ...

Fla., praised news that President Donald Trump will reinstate service members expelled for refusing to take the COVID-19 ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech that'll never recover its former glory -- which it built on the success of its ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain ...

SINGAPORE: The updated JN.1 Novavax/Nuvaxovid COVID-19 vaccine will be offered under the national vaccination programme at ...

Plus: Moderna’s bird flu vaccine, Obamacare enrollment breaks records, and AstraZeneca’s new breast cancer treatment is FDA ...